Next-generation sequencings tests are just starting to change the landscape for cancer patients, explained Peter Paul Yu, MD, FASCO, FACP, physician-in-chief, Hartford HealthCare Cancer Center.
Next-generation sequencings tests are just starting to change the landscape for cancer patients, explained Peter Paul Yu, MD, FASCO, FACP, physician-in-chief, Hartford HealthCare Cancer Center.
Transcript
How is next-generation sequencing changing the landscape for cancer care?
Next-generation sequencings tests are just starting to change the landscape for cancer patients. We’ve had quite a bit of FDA and CMS regulation just in the first half of this year, which have begun to lay down the road map for how the FDA will look at laboratory diagnostic tests based on genomics and how they will go about ascertaining the quality of that test and how CMS is starting to think about how they will decide when they will pay for these tests. So, the fact that we have the 2 major regulatory agencies in the United States starting to set policy is a big step forward.
However, the payment policy issued by the National Coverage Decision by CMS a couple of months ago is extremely narrow. It essentially, as I interpret it, limits it to when there is a specific genomic biomarker match to a specific drug that’s been FDA approved. In that circumstance, combined with a patient with advanced cancer, there will be payment for it. But, it’s still a very, very limited role.
The alternative is that we rely on traditional biomarker testing, which is either a series of sequential tests that consume a lot of sample, and very often you may run out of sample before you’ve done all your testing, or some limited panel, which is increasingly being look at as both an inefficient and expensive way of doing genomic testing.
So, I think that it’s good news that the FDA and CMS are recognizing that requiring a specific companion diagnostic test for every single drug that is precision medicine-based is no longer the way to go. But, we’re not quite there yet.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More